Syndax Pharmaceuticals SNDX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$42.67M+49.7% | -$68.01M+27.8% | -$60.72M+27.8% | -$71.85M-5.6% | -$84.85M-17.2% | ||
| $12.05M+16.1% | $11.25M-8.5% | $12.08M+1.2% | $13.79M+39.3% | $10.38M+16.6% | ||
| $56K-50.0% | $0-100% | $62K— | $55K— | $112K— | ||
| -$120K-101% | $12.59M+65.7% | $5.95M— | $3.73M— | $8.12M— | ||
| $2.06M-50.8% | $7.8M+2,031% | $7.18M— | $12.92M— | $4.19M— | ||
| -$5.74M-263% | $2.75M-59.1% | —— | $7.31M+165% | -$1.58M-37.1% | ||
| -$28.35M-1,019% | $25.7M+120% | $1.1M-94.8% | $17.9M+362% | -$2.53M+62.2% | ||
| -$7.84M-30.8% | $5.4M— | $4.36M-59.1% | $10.77M— | -$5.99M-310% | ||
| —— | $0+100% | —— | —— | —— | ||
| -$6.14M-13,538% | $6.4M+4,903% | $38K— | $39K-98.9% | -$45K-101% | ||
| -$50.35M+47.1% | -$69.49M-21.1% | -$70.54M-13.2% | -$87.8M-22.5% | -$95.16M-13.9% | ||
| $39.39M+274% | $63.12M-83.2% | $30.44M+128% | $91.71M— | $10.54M-93.7% | ||
| $77.78M-25.7% | $144.75M+34.9% | $103M+2.8% | $133.6M+116% | $104.68M+54.0% | ||
| $38.39M-59.2% | $81.58M+130% | $72.43M-16.6% | $41.89M— | $94.14M+195% | ||
| $7.92M+751% | $5.92M-98.3% | $6.28M+103% | $551K-18.5% | $930K-57.1% | ||
| -$4.04M-4,386% | —— | —— | -$45.36M-392% | -$90K+100.0% | ||
| $862K-76.0% | $1.53M-48.0% | $2.41M-21.1% | $3.21M-12.0% | $3.6M-5.8% | ||
| $56K-50.0% | $0-100% | $62K— | $55K— | $112K— | ||
| $4K— | $3K— | $3K+50.0% | $0-100% | $0-100% | ||
| -$6.14M-13,538% | $6.4M+4,903% | $38K— | $39K-98.9% | -$45K-101% | ||
| -$28.35M-1,019% | $25.7M+120% | $1.1M-94.8% | $17.9M+362% | -$2.53M+62.2% | ||
| $3.24M+146% | -$8.01M-158% | -$3.42M-242% | -$24.5M-451% | -$7.04M-2,336% | ||
| -$7.84M-30.8% | $5.4M— | $4.36M-59.1% | $10.77M— | -$5.99M-310% | ||
| —— | $40.75K— | $40.75K— | $40.75K— | $40.75K— | ||
| $130K-41.2% | $395K+89.9% | $158K-46.4% | $172K-28.9% | $221K-9.4% | ||
| —— | $916.75K— | $916.75K— | $916.75K— | $916.75K— | ||
| $39.39M+274% | $63.12M-83.2% | $30.44M+128% | $91.71M— | $10.54M-93.7% | ||
| $77.78M-25.7% | $144.75M+34.9% | $103M+2.8% | $133.6M+116% | $104.68M+54.0% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $458K-16.0% | $605K-4.6% | $0-100% | $468K+97.5% | $545K+76.4% | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Syndax Pharmaceuticals's cash flow data come from?
- Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.